In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory MM had high rates of very good partial responses (VGPRs) or better to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology (ASH) Annual Meeting [25]. Here, TNFRSF17 is linked to Miyoshi myopathy.